Associated Papers
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer.
Chamberlin MD et al.
Breast Cancer Research and Treatment, 2020
Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families.
de Garibay GR et al.
European Journal of Human Genetics : Ejhg, 2013
Assessment of SLX4 Mutations in Hereditary Breast Cancers.
Shah S et al.
Plos One, 2013
Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.
Fernández-Rodríguez J et al.
Bmc Cancer, 2012
Select a paper to view details